These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8450670)

  • 1. Minimally differentiated acute leukemia.
    Cadwell FJ; Burns CP; Dick FR; Jones MP; Heckman KD; Weiner GJ; Goeken JA
    Leuk Res; 1993 Mar; 17(3):199-208. PubMed ID: 8450670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.
    Huang SY; Tang JL; Jou ST; Tsay W; Hu CH; Lin DT; Lin KS; Lin KS; Wang CH; Chen YC; Shen MC; Tien HF
    Leukemia; 1999 Oct; 13(10):1506-12. PubMed ID: 10516750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.
    Paietta E; Neuberg D; Bennett JM; Dewald G; Rowe JM; Cassileth PA; Cripe L; Tallman MS; Wiernik PH;
    Leukemia; 2003 Aug; 17(8):1544-50. PubMed ID: 12886241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
    Suzuki R; Ohtake S; Takeuchi J; Nagai M; Kodera Y; Hamaguchi M; Miyawaki S; Karasuno T; Shimodaira S; Ohno R; Nakamura S; Naoe T
    Int J Hematol; 2010 Mar; 91(2):303-9. PubMed ID: 20111912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD7 expression in acute myeloid leukemia.
    Del Poeta G; Stasi R; Venditti A; Cox C; Aronica G; Masi M; Bruno A; Simone MD; Buccisano F; Papa G
    Leuk Lymphoma; 1995 Mar; 17(1-2):111-9. PubMed ID: 7539657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
    Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
    Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
    Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
    J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lineage identification of acute leukemias: relevance of immunologic and ultrastructural techniques.
    Stasi R; Del Poeta G; Venditti A; Bruno A; Suppo G; Aronica G; Di Carlo G; Papa G
    Hematol Pathol; 1995; 9(2):79-94. PubMed ID: 7559258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute lymphoblastic leukemia following preleukemic syndromes in adults.
    Escudier SM; Albitar M; Robertson LE; Andreeff M; Pierce S; Kantarjian HM
    Leukemia; 1996 Mar; 10(3):473-7. PubMed ID: 8642864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
    Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
    Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study.
    Delacrétaz F; Spertini O; Schmidt PM; Grob JP
    Pathol Res Pract; 1991 Mar; 187(2-3):290-5. PubMed ID: 2068013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of the diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-MO).
    Iwata H; Kami M; Kishi Y; Oki Y; Tanaka Y; Takeuchi K; Yamazaki I; Suzuki R; Morinaga S; Mutou Y
    Leukemia; 2000 Nov; 14(11):2013-4. PubMed ID: 11069040
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.